1Reid DM,Devogelaer JP,Saag K,et al.Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON):a multicentre,double-blind,double-dummy,randomised controlled trial[J].Lancet,2009,373(9671):1253-1263.
2van Staa TP,Geusens P,Pols HA,et al.A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids[J].QJM,2005,98(3):191-198.
3American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update[J].Arthritis Rheum,2001,44(7):1496-1503.
4Netelenbos JC,Geusens PP,Ypma G,et al.Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale,long-term retrospective study in The Netherlands[J].Osteoporos Int,2010,22 (5):1537-1546.
5Saag KG,Zanchetta JR,Devogelaer JP,et al.Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis:thirty-six-month results of a randomized,double-blind,controlled trial[J].Arthritis Rheum,2009,60(11):3346-3355.
9Redlich K,Zieler S,Kiener HP,et al.Bone mineral density and bi-ochemical parameters of bone metabolism in female patients withsystemic lupus erythematosus[J].Ann Rheum Dis,2000,59(4):308-310.
10Lee C,Goldman R.Osteopemsis in systemic lupus erythematosusmechanisms[J].Rheum Dis Clin North Am,2005,31(2):363-385.
